1. Home
  2. CORT vs VNO Comparison

CORT vs VNO Comparison

Compare CORT & VNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CORT
  • VNO
  • Stock Information
  • Founded
  • CORT 1998
  • VNO 1946
  • Country
  • CORT United States
  • VNO United States
  • Employees
  • CORT N/A
  • VNO N/A
  • Industry
  • CORT Biotechnology: Pharmaceutical Preparations
  • VNO Real Estate Investment Trusts
  • Sector
  • CORT Health Care
  • VNO Real Estate
  • Exchange
  • CORT Nasdaq
  • VNO Nasdaq
  • Market Cap
  • CORT 7.5B
  • VNO 7.0B
  • IPO Year
  • CORT N/A
  • VNO N/A
  • Fundamental
  • Price
  • CORT $71.72
  • VNO $38.60
  • Analyst Decision
  • CORT Strong Buy
  • VNO Hold
  • Analyst Count
  • CORT 4
  • VNO 11
  • Target Price
  • CORT $142.00
  • VNO $37.91
  • AVG Volume (30 Days)
  • CORT 1.6M
  • VNO 2.0M
  • Earning Date
  • CORT 07-28-2025
  • VNO 08-04-2025
  • Dividend Yield
  • CORT N/A
  • VNO 1.92%
  • EPS Growth
  • CORT 8.36
  • VNO 248.25
  • EPS
  • CORT 1.14
  • VNO 0.52
  • Revenue
  • CORT $685,446,000.00
  • VNO $1,929,890,000.00
  • Revenue This Year
  • CORT $35.83
  • VNO N/A
  • Revenue Next Year
  • CORT $35.24
  • VNO $4.97
  • P/E Ratio
  • CORT $62.92
  • VNO $73.59
  • Revenue Growth
  • CORT 30.93
  • VNO 2.98
  • 52 Week Low
  • CORT $30.77
  • VNO $26.19
  • 52 Week High
  • CORT $117.33
  • VNO $46.63
  • Technical
  • Relative Strength Index (RSI)
  • CORT 50.50
  • VNO 50.76
  • Support Level
  • CORT $66.49
  • VNO $37.45
  • Resistance Level
  • CORT $72.49
  • VNO $38.88
  • Average True Range (ATR)
  • CORT 2.85
  • VNO 1.22
  • MACD
  • CORT -0.09
  • VNO -0.05
  • Stochastic Oscillator
  • CORT 49.95
  • VNO 59.66

About CORT Corcept Therapeutics Incorporated

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.

About VNO Vornado Realty Trust

Vornado owns and has an ownership interest in Class A office and retail properties highly concentrated in Manhattan, with additional properties in San Francisco and Chicago. It operates as a real estate investment trust.

Share on Social Networks: